CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNSP CNS Pharmaceuticals, Inc.

Pre-Market Trading 05-03 06:58:37 EDT

0.2155

-0.0025

-1.14%

High0.2290	Low0.2100	Vol112.15K
Open0.2140	D1 Closing0.2180	Amplitude8.72%
Mkt Cap2.29M	Tradable Cap1.93M	Total Shares10.63M
T/O24.71K	T/O Rate1.25%	Tradable Shares8.95M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CNSP","market":"US","secType":"STK","nameCN":"CNS Pharmaceuticals, Inc.","latestPrice":0.215518,"timestamp":1714680000000,"preClose":0.218,"halted":0,"volume":112152,"delay":0,"floatShares":8946951,"shares":10634932,"eps":-5.003813,"marketStatus":"Pre-Market Trading","change":-0.002482,"latestTime":"05-03 06:58:37 EDT","open":0.214,"high":0.229,"low":0.21,"amount":24712.179543839997,"amplitude":0.087156,"askPrice":0.2402,"askSize":100,"bidPrice":0.1843,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.003813,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1714743000000},"marketStatusCode":1,"adr":0,"listingDate":1573189200000,"exchange":"NASDAQ","adjPreClose":0.2161,"postHourTrading":{"tag":"盘后","latestPrice":0.2141,"preClose":0.215518,"latestTime":"19:24 EDT","volume":646,"amount":138.4276,"timestamp":1714692269775},"volumeRatio":1.3907634631335668},"requestUrl":"/m/hq/s/CNSP","defaultTab":"news","newsList":[{"id":"2429319252","title":"CNS Pharmaceuticals to Present at the LSX World Congress 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2429319252","media":"ACCESSWIRE","top":-1,"share":"https://ttm.financial/m/news/2429319252?lang=en_us&edition=fundamental","pubTime":"2024-04-23 21:00","pubTimestamp":1713877200,"startTime":"0","endTime":"0","summary":"Presentation on Monday, April 29th at 4:15 PM . HOUSTON, TX / ACCESSWIRE / April 23, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the LSX World Congress 2024 on Monday, April 29, 2024 at 4:15 PM  in London, England.In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, visit the conference website.About CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Beru","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/yR8pIXRHC9bj18Gcah0sVw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/f41120e54ed2e3dcc090d6d1b34ae469","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/yR8pIXRHC9bj18Gcah0sVw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/f41120e54ed2e3dcc090d6d1b34ae469"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-present-lsx-world-130000204.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429290314","title":"BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Spotlighted in Upcoming Virtual Investor Lunch Break Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2429290314","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2429290314?lang=en_us&edition=fundamental","pubTime":"2024-04-23 03:40","pubTimestamp":1713814800,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured on the Virtual Investor Lunch Break: The CNSP Opportunity event. During the live video webcast, which is scheduled to begin at 12 p.m. EST, CEO John Climaco will present a corporate overview. He will also discuss the company’s business outlook and opportunity. In addition, the event provides an opportunity for those participating to submit questions; Climaco will answer as many questions as possible I the time provided. A replay of the presentation will be available for 90 days shortly after the presentation has ended.To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23096442","is_publish_highlight":false,"gpt_icon":0},{"id":"2429222499","title":"CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2429222499","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2429222499?lang=en_us&edition=fundamental","pubTime":"2024-04-22 22:17","pubTimestamp":1713795420,"startTime":"0","endTime":"0","summary":"Live video webcast with Chief Executive Officer, John Climaco, on Tuesday, April 23rd at 12:00 PM ETHOUSTON, TX / ACCESSWIRE / April 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23095080","is_publish_highlight":false,"gpt_icon":0},{"id":"2427383528","title":"BioMedNewsBreaks — CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2427383528","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2427383528?lang=en_us&edition=fundamental","pubTime":"2024-04-16 03:15","pubTimestamp":1713208500,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme , an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23067354","is_publish_highlight":false,"gpt_icon":0},{"id":"2427637075","title":"CNS Pharmaceuticals Conducts Informational Investor Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2427637075","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2427637075?lang=en_us&edition=fundamental","pubTime":"2024-04-15 18:22","pubTimestamp":1713176552,"startTime":"0","endTime":"0","summary":"The latest update is out from CNS Pharmaceuticals (CNSP). CNS Pharmaceuticals, Inc. is engaging with the investment community through a series of m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cns-pharmaceuticals-conducts-informational-investor-meetings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cns-pharmaceuticals-conducts-informational-investor-meetings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2425914640","title":"Researchers Link Hormone Treatments to Heightened Risk of Brain Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2425914640","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2425914640?lang=en_us&edition=fundamental","pubTime":"2024-04-08 23:10","pubTimestamp":1712589000,"startTime":"0","endTime":"0","summary":"Scientists at the National Agency for Medicines and Health Products Safety in France recently linked the use of hormone treatments by women to a heightened risk of women developing benign brain tumors. During their research, they determined that prolonged use of some progestogen drugs was associated with a higher risk of meningioma.This sentiment isn’t shared by all, however, with one leading expert noting that while the risk of meningioma was higher in women who took the…BMW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23039336","is_publish_highlight":false,"gpt_icon":0},{"id":"2424027959","title":"BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2424027959","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2424027959?lang=en_us&edition=fundamental","pubTime":"2024-04-03 01:30","pubTimestamp":1712079000,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme , an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com.BioMedWire  is a specialized communications platform with a focus on the latest developments in the Biotechnology , Biomedical Sciences  and Life Sciences sectors. It is one o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23014693","is_publish_highlight":false,"gpt_icon":0},{"id":"2424101185","title":"CNS Pharmaceuticals Q4 EPS $(0.95) Up From $(3.82) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2424101185","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2424101185?lang=en_us&edition=fundamental","pubTime":"2024-04-02 20:10","pubTimestamp":1712059827,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(0.95) per share. This is a 75.13 percent increase over losses of $(3.82) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/04/38043519/cns-pharmaceuticals-q4-eps-0-95-up-from-3-82-yoy","is_publish_highlight":false,"gpt_icon":0},{"id":"2424774712","title":"CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2424774712","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2424774712?lang=en_us&edition=fundamental","pubTime":"2024-04-02 05:02","pubTimestamp":1712005320,"startTime":"0","endTime":"0","summary":"Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM studyBerubicin stu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23008948","is_publish_highlight":false,"gpt_icon":0},{"id":"2424143687","title":"CNS Pharmaceuticals to Present at Two Investor Conferences in April","url":"https://stock-news.laohu8.com/highlight/detail?id=2424143687","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2424143687?lang=en_us&edition=fundamental","pubTime":"2024-04-01 21:07","pubTimestamp":1711976820,"startTime":"0","endTime":"0","summary":"HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23004672","is_publish_highlight":false,"gpt_icon":0},{"id":"2421916089","title":"US Military Desperately Seeking To Stay In Niger Despite Order To Leave","url":"https://stock-news.laohu8.com/highlight/detail?id=2421916089","media":"Zero Hedge","top":-1,"share":"https://ttm.financial/m/news/2421916089?lang=en_us&edition=fundamental","pubTime":"2024-03-21 00:00","pubTimestamp":1710950400,"startTime":"0","endTime":"0","summary":"— Ra","market":"us","thumbnail":"https://cms.zerohedge.com/s3/files/styles/teaser_desktop_2x/public/2024-03/dronebasefile1.jpg?itok=j7HaE9TI","type":0,"news_type":0,"thumbnails":["https://cms.zerohedge.com/s3/files/styles/teaser_desktop_2x/public/2024-03/dronebasefile1.jpg?itok=j7HaE9TI"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zerohedge.com/military/us-military-desperately-seeking-stay-niger-despite-order-leave","is_publish_highlight":false,"gpt_icon":0},{"id":"2420790286","title":"CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2420790286","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2420790286?lang=en_us&edition=fundamental","pubTime":"2024-03-19 02:35","pubTimestamp":1710786900,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals recently appointed Amy Mahery, a biotech commercialization leader, to its Board of Directors. Ms. Mahery brings over 20 years’ experience, having worked with small and large companies, and has held diverse commercial leadership roles in the U.S. and globally. The company believes Ms. Mahery’s guidance, insight, and vast pharma industry network will indeed be invaluable as the company advances Berubicin, its flagship drug candidate, toward completion of its global potentially pivotal clinical trial and potential regulatory approval. The company recently completed the enrollment of patients in its potentially pivotal global clinical trial. Ms. Mahery believes Berubicin represents an opportunity to provide a solution for patients with GBM, the most aggressive type of brain cancer. A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and la","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22944459","is_publish_highlight":false,"gpt_icon":0},{"id":"2420401690","title":"New Research Sheds Light on the Initial Stages of Brain Cancer Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2420401690","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2420401690?lang=en_us&edition=fundamental","pubTime":"2024-03-18 23:40","pubTimestamp":1710776400,"startTime":"0","endTime":"0","summary":"Recent research has identified processes that could lead to the growth of tumors. The research was conducted by a team at the University of Plymouth’s Brain Tumour Research Centre, led by Dr. Claudia Barros.This institution is focused on providing new understanding of certain groups of common, low-grade brain tumors. For their research, the investigators used…BMW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22943651","is_publish_highlight":false,"gpt_icon":0},{"id":"2414131334","title":"CNS Pharmaceuticals Strives to Regain Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2414131334","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2414131334?lang=en_us&edition=fundamental","pubTime":"2024-02-28 06:33","pubTimestamp":1709073199,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (CNSP) has provided an announcement. CNS Pharmaceuticals, Inc. faces a challenge maintaining its Nasdaq listing after the stock...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cns-pharmaceuticals-strives-to-regain-nasdaq-compliance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cns-pharmaceuticals-strives-to-regain-nasdaq-compliance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2409431509","title":"Scientists Start Trialing First Blood Test Against Brain Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2409431509","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2409431509?lang=en_us&edition=fundamental","pubTime":"2024-02-05 23:55","pubTimestamp":1707148500,"startTime":"0","endTime":"0","summary":"Brain tumors, which affects thousands of individuals around the globe, can be diagnosed using various imaging techniques, including magnetic resonance imaging  and computed tomography  scans. Some tumors cannot be diagnosed using these techniques, however, which makes it hard for them to be detected earlier.In the United Kingdom, brain tumors kill more individuals aged 40 and below than any other cancer. Now, researchers have developed a blood test that…BMW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22720143","is_publish_highlight":false,"gpt_icon":0},{"id":"2408917576","title":"CNS Pharmaceuticals Announces Board Changes and New Consultant","url":"https://stock-news.laohu8.com/highlight/detail?id=2408917576","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2408917576?lang=en_us&edition=fundamental","pubTime":"2024-02-03 17:39","pubTimestamp":1706953173,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (CNSP) has released an update to notify the public and investors about its officers. On January 17, 2024, Amy Mahery was appoin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cns-pharmaceuticals-announces-board-changes-and-new-consultant?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cns-pharmaceuticals-announces-board-changes-and-new-consultant?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2408191757","title":"CNS Pharmaceuticals Launches Public Offering for Trial Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2408191757","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2408191757?lang=en_us&edition=fundamental","pubTime":"2024-02-03 17:39","pubTimestamp":1706953158,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (CNSP) has released an update to notify the public and investors about an entry into a material definitive agreement. On Januar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cns-pharmaceuticals-launches-public-offering-for-trial-funding?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cns-pharmaceuticals-launches-public-offering-for-trial-funding?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2407363114","title":"BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Information on $4M Public Offering Pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=2407363114","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2407363114?lang=en_us&edition=fundamental","pubTime":"2024-01-30 23:15","pubTimestamp":1706627700,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme , an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com.BioMedWire  is a specialized communications platform with a focus on the latest developments in the Biotechnology , Biomedical Sciences  and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers:  access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demograp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22693307","is_publish_highlight":false,"gpt_icon":0},{"id":"2407449804","title":"CNS Pharmaceuticals prices $4M public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2407449804","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2407449804?lang=en_us&edition=fundamental","pubTime":"2024-01-30 15:19","pubTimestamp":1706599153,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals  priced public offering with participation from healthcare-focused institutional investors and certain officers and directors of the company for the purchase and sale of 13,333,334 shares at a purchase price of $0.30 per share.The company further agreed to issue to the investors Series A Warrants to purchase up to 13,333,334 shares and Series B Warrants to purchase up to 13,333,334 shares.The closing of the offering is expected to occur on or about February 1, 2024. Stock price wasup 3.6%on Tuesday during pre-market trading.More on CNS Pharmaceuticals  Financial information for CNS Pharmaceuticals","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4059804-cns-pharmaceuticals-prices-4m-public-offering","is_publish_highlight":false,"gpt_icon":0},{"id":"2407431824","title":"CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2407431824","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2407431824?lang=en_us&edition=fundamental","pubTime":"2024-01-30 10:01","pubTimestamp":1706580060,"startTime":"0","endTime":"0","summary":"HOUSTON, TX / ACCESSWIRE / January 29, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for pri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22690551","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cnspharma.com","stockEarnings":[{"period":"1week","weight":0.0565},{"period":"1month","weight":-0.2991},{"period":"3month","weight":-0.1379},{"period":"6month","weight":-0.8922},{"period":"1year","weight":-0.8878},{"period":"ytd","weight":-0.8303}],"compareEarnings":[{"period":"1week","weight":0.0031},{"period":"1month","weight":-0.0266},{"period":"3month","weight":0.0216},{"period":"6month","weight":0.1618},{"period":"1year","weight":0.2378},{"period":"ytd","weight":0.0625}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.194164},{"month":2,"riseRate":0.4,"avgChangeRate":-0.000171},{"month":3,"riseRate":0.2,"avgChangeRate":-0.161933},{"month":4,"riseRate":0.4,"avgChangeRate":0.057823},{"month":5,"riseRate":0.4,"avgChangeRate":-0.002679},{"month":6,"riseRate":0.5,"avgChangeRate":-0.000147},{"month":7,"riseRate":0.25,"avgChangeRate":-0.113799},{"month":8,"riseRate":0.5,"avgChangeRate":0.003337},{"month":9,"riseRate":0,"avgChangeRate":-0.226463},{"month":10,"riseRate":0.25,"avgChangeRate":0.147818},{"month":11,"riseRate":0.5,"avgChangeRate":-0.055065},{"month":12,"riseRate":0,"avgChangeRate":-0.243828}],"exchange":"NASDAQ","name":"CNS Pharmaceuticals, Inc.","nameEN":"CNS Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CNS Pharmaceuticals, Inc.,CNSP,CNS Pharmaceuticals, Inc.股票,CNS Pharmaceuticals, Inc.股票老虎,CNS Pharmaceuticals, Inc.股票老虎国际,CNS Pharmaceuticals, Inc.行情,CNS Pharmaceuticals, Inc.股票行情,CNS Pharmaceuticals, Inc.股价,CNS Pharmaceuticals, Inc.股市,CNS Pharmaceuticals, Inc.股票价格,CNS Pharmaceuticals, Inc.股票交易,CNS Pharmaceuticals, Inc.股票购买,CNS Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction